Zydus Cadila: News
Zydus Cadila is a multinational pharmaceutical company based in Ahmedabad, Gujarat. The company is also known as Cadila Healthcare Limited and is primarily engaged in the manufacturing of generic drugs. In 2020, it ranked 100 on the Fortune India 500 list. Cadila was founded in 1952 by Ramanbhai B. Patel (late) and his business partner Indravadan Modi. In 1995, the Patel and Mody families split and the latter's share was moved into a new company called Cadila Pharmaceuticals Limited. Cadila Healthcare remained the Patel family’s holding. It made its initial public offering on the Bombay Stock Exchange in 2000. In the fiscal year 2021, Cadila healthcare generated total revenue of ₹15,139 crores, of which the company's net income was ₹2,133 crores. As of 2021, Zydus Cadila employs 25,000 people. This is a stellar growth for Zydus Cadila that had a turnover of ₹250 crores in 1995 when the families split.
Zydus Lifesciences to acquire 50% stake in Sterling Biotech
Zydus Lifesciences has announced its intention to acquire a 50% stake in Sterling Biotech.
Zydus Lifesciences receives US approval for generic HIV-1 drug
Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA), to market its generic Darunavir tablets in the country.
Are Indian vaccines effective against Omicron? Here's what manufacturers say
The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.
ZyCoV-D expected to be rolled out in two weeks: Report
The indigenous COVID-19 vaccine developed by Zydus Cadila, called ZyCoV-D, is likely to be rolled out in the next two weeks.
Here are some key drugs being tested for COVID-19 treatment
Several antiviral drugs are being developed and tested for COVID-19 treatment as scientists around the world race to find new methods to fight the pandemic and ease the burden on hospitals.
NTAGI to devise roadmap to introduce ZyCoV-D into inoculation drive
The National Technical Advisory Group on Immunization (NTAGI) will soon hold a meeting to devise a roadmap for introducing Zydus Cadila's COVID-19 vaccine in the inoculation drive and prioritizing beneficiaries focusing on those aged 12-18 years with comorbidities.
COVID-19 vaccine trials for ages 3-12 soon: Zydus Cadila MD
After receiving emergency use approval for its COVID-19 vaccine, Zydus Cadila will now submit an application to start vaccine trials for children aged 3-12 years, Managing Director Dr. Sharvil Patel said Saturday.
Zydus Cadila's COVID-19 vaccine approved. What you need to know
Zydus Cadila's three-dose coronavirus vaccine has received the emergency use authorization from India's top drug regulator, becoming the sixth jab to get the nod in the country.
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday.
Zydus Cadila COVID-19 vaccine may get emergency nod this week
India's second indigenous COVID-19 vaccine, developed by Zydus Cadila, is reportedly likely to get emergency use approval (EUA) this week.
Zydus vaccine for 12-18-year-olds from September, says expert panel chief
Coronavirus vaccination for children with the Zydus Cadila vaccine will start by September, said Dr. NK Arora, the chief of National Expert Group on Vaccine Administration.
Zydus applies for approval of its 3-dose, needle-free COVID-19 vaccine
Zydus Cadila, the Gujarat-based drug firm, has applied for the Emergency Use Authorization (EUA) of its COVID-19 vaccine to the Drugs Controller General of India (DCGI), the company said today.
Zydus to seek approval for its COVID-19 vaccine next week
Zydus Cadila, the Gujarat-based drug firm, will next week apply for the emergency use authorization (EUA) of its COVID-19 vaccine in India, company sources told the media, adding it has apprised the government of its intention.
Zydus seeks human trial approval for its COVID-19 antibody cocktail
Indian pharmaceutical firm Zydus Cadila has sought permission from the Drugs Controller General of India (DCGI) to conduct human clinical trials of its antibody cocktail meant to treat mild COVID-19 patients.
Zydus Cadila's antiviral drug approved for treating moderate COVID-19 cases
The Drugs Controller General of India (DCGI) on Friday gave approval for the emergency use of Zydus Cadila's Hepatitis C drug "Virafin" for the treatment of moderate coronavirus infection in adults.
India's neighbors train experts for clinical trials of COVID-19 vaccine
India's friendly neighboring nations trained over 100 experts to strengthen capacities in their countries for facilitating phase-3 clinical trials of the Indian COVID-19 vaccine, a senior official of the Department of Biotechnology said.
Applying for Covishield's emergency approval in 2 weeks: SII
The CEO of the Serum Institute of India (SII), Adar Poonawalla, on Saturday said that the company will seek the emergency-use authorization of the coronavirus vaccine 'Covishield' soon.
Modi embarks on 3-city tour to view COVID-19 vaccine development
Prime Minister Narendra Modi on Saturday embarked on a three-city tour to review the development of COVID-19 vaccines.
Coronavirus: Zydus Cadila launches cheapest version of Remdesivir in India
In a major development, Zydus Cadila has launched the cheapest generic version of Remdesivir, the antiviral drug being used to treat COVID-19, in India.
Zydus Cadila's COVID-19 vaccine found safe, going into Phase-2 trial
Indian drug company Zydus Cadila has completed early-stage human trials with its indigenously developed COVID-19 vaccine.
India's COVID-19 vaccines: What are the latest updates?
In the race to develop a vaccine for the novel coronavirus disease (COVID-19), two pharma companies are leading the way from India - Bharat Biotech and Zydus Cadila.
COVID-19 vaccine: What are the latest updates?
With more than 5.3 lakh deaths and 1.14 crore infections, the COVID-19 pandemic continues to grow worse around the world.
India's second COVID-19 vaccine cleared for human trials: Details here
India is picking up pace to develop a preventive vaccine for COVID-19, the novel coronavirus disease.
COVID KAVACH ELISA: First Indian antibody detection kit for coronavirus
In a major step forward, the Indian Council of Medical Research and National Institute of Virology have jointly announced the development of COVID KAVACH ELISA, the first indigenous antibody detection kit for COVID-19.
GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance
Amid an ongoing probe into Ranitidine's reported cancer-causing impurities, GlaxoSmithKline Pharmaceuticals Limited (GSK) has recalled Ranitidine-based antacid Zinetac (150mg and 300mg) in India and other markets.